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OBJECTIVES The aim of this study was to investigate whether myocardial inflammation (MC) and
endothelial activation are associated with clinically detectable endothelial dysfunction.
BACKGROUND In patients with MC, immunohistologic evaluation of myocardial biopsies demonstrates a
cellular infiltrate of lymphocytes in the myocardium and endothelial activation, as indicated
by enhanced expression of human leukocyte antigen (HLA)-1, HLA-DR and intercellular
adhesion molecule (ICAM)-1. This chronic inflammatory process may be associated with
endothelial dysfunction.
METHODS In 65 patients with suspected MC, endothelial function of the radial artery was noninvasively
assessed. By means of high-resolution ultrasound, diameter changes in response to reactive
hyperemia (endothelium-dependent), as compared with glyceroltrinitrate (endothelium-
independent), were analyzed. In the myocardial biopsies, MC was confirmed by immuno-
histology in 53 patients; 12 patients with normal myocardial biopsies served as controls.
Endothelial expression of HLA-1, HLA-DR and ICAM-1 was semiquantitatively evaluated
by immunohistology. To minimize other factors influencing endothelial function, patients
with coronary artery disease, diabetes, severely impaired left ventricular function or more than
one arteriosclerotic risk factor were excluded from this study.
RESULTS Endothelial function, as determined by flow-mediated vasodilation (FMD), in patients with
MC was impaired (FMDMC 4.28%), as compared with controls (FMDCo 10.10%). The
severity of endothelial dysfunction in patients with MC correlated significantly with the
extent of endothelial expression of HLA-1, HLA-DR and ICAM-1 in myocardial biopsies.
Endothelium-independent vasodilation was not affected by MC or endothelial activation.
CONCLUSIONS Myocardial inflammation is associated with endothelial dysfunction of peripheral arteries.
The severity of endothelial dysfunction correlates with the extent of endothelial
activation. (J Am Coll Cardiol 2002;40:515–20) © 2002 by the American College of
Cardiology Foundation
Endothelial function plays a central roll in the development
of vascular disease and represents a marker of prognostic
relevance; endothelial dysfunction in coronary artery disease
is associated with increased development of adverse coro-
nary events (1,2). After heart transplantation, endothelial
dysfunction anticipates the development of transplant vas-
culopathy and transplant failure (3–5). Endothelial dysfunc-
tion has been observed in association with acute systemic
inflammatory immune responses (6,7). It has been corre-
lated with levels of C-reactive protein (8). Furthermore,
clinical studies have shown that endothelial function can be
restored by suppression of inflammation in patients with
systemic vasculitis (9).
Immunohistologic evaluation of myocardial biopsies in
patients with myocardial inflammation (MC) demonstrates
a myocardial lymphocyte infiltrate and endothelial activa-
tion that can be detected by enhanced expression of cell
adhesion molecules (CAMs) (10,11). Thus, the vessel wall
is involved in the inflammatory process. Cell adhesion
molecule expression is generally regulated by proinflamma-
tory cytokines that can effect not only the local vasculature
in the heart, but also, systemically, the peripheral vessels. A
correlation between coronary and peripheral endothelial
function has been demonstrated for other diseases (12). The
aim of the study presented here was to investigate whether
the inflammatory process in the myocardium leads to a
systemic deterioration of endothelial function. Furthermore,
we aimed to elucidate if the severity of endothelial dysfunc-
tion in patients with MC correlates with the extent of
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endothelial activation, as detected by enhanced expression
of human leukocyte antigen (HLA)-1, HLA-DR and
intercellular adhesion molecule (ICAM)-1 in myocardial
biopsies.
METHODS
Study population. We included 65 consecutive patients
with suspected MC, considering clinical symptoms and
noninvasive testing as electrocardiogram (ECG), echocar-
diography or spiroergometry. When coronary artery disease
was excluded by angiography, myocardial biopsies were
obtained to establish a diagnosis. According to the findings
in the myocardial biopsies, the patients were divided into a
group with MC and a control group (Co). In 53 patients,
MC was confirmed by immunohistology in myocardial
biopsies; 12 patients had normal myocardial biopsies (Co).
To minimize other confounding factors on endothelial
dysfunction, patients with coronary artery disease (1,2),
diabetes (13), more than one risk factor for arteriosclerosis
(13–16), overt arteriosclerosis or other severe disease, like
malignancy, autoimmune disorders, renal or hepatic failure
or recent operations, were excluded from this study. As
heart failure is known to affect endothelial function (17–22),
we excluded patients with severely impaired left ventricular
contractility (ejection fraction [EF] 35%). At the time of
the study, the majority of patients was already on cardio-
vascular medication, which is known to influence endothe-
lial function (23–25). To exclude acute effects, all cardio-
vascular medication was ceased 12 h to 48 h before the
study, depending on half-life. Patients were required to have
sinus rhythm. Of 74 patients screened, 9 had exclusion
criteria; 65 met the inclusion criteria.
Informed consent was obtained from all patients; the
study protocol was approved by the local Ethics Committee
of the Free University of Berlin.
Myocardial biopsies. SAMPLE PREPARATION. Endomyo-
cardial biopsies from the right ventricular septum were
obtained by standard percutaneous transvenous femoral
approach with a standard bioptome. For immunohistologic
evaluation, the samples were prepared as published previ-
ously (11); biopsies were embedded in Tissue Tec (Sakura
Finetek Europe, Zouterwoude, The Netherlands), immedi-
ately snap-frozen in methylbutane, cooled in liquid nitrogen
at 70°C and then serially cut into cryosections of 5 m
thickness. Six to nine sections from a single biopsy were
analyzed for each antibody per patient. After fixation in cold
acetone, endogenous peroxidase activity was quenched by
incubating the cryosections with 0.3% H2O2 in phosphate
buffered solution (Dulbeco, Seromed Biochrom, Berlin,
Germany). The cryosections were then incubated with
monoclonal mouse antibody in PBS, containing 5% heat-
inactivated fetal calf serum (Seromed Biochrom) (saturation
of unspecific protein binding sites). The slides were incu-
bated with peroxidase-conjugated polyclonal rabbit anti-
mouse antibody, dilution 1:200 (Dianova, Hamburg, Ger-
many). Immunoreactive staining was developed by use of
3-amino-9-ethylcarbazole (Merck, Germany), being con-
verted by peroxidase to a red precipitate. The antibodies
used are commercially available from Dianova (anti-HLA)
and Serva (anti-ICAM).
IMMUNOHISTOLOGIC EVALUATION. Immunohistologically
stained leucocytes were counted per high-power field (400-
fold magnification, 0.28 mm2) by use of a Leica (Bensheim,
Germany) MDRD microscope in all available fields (10
fields per antibody). The mean cell counts per high-power
field were computed. Myocardial inflammation was con-
firmed in myocardial biopsies, if more than seven CD3
lymphocytes per 1 mm2 tissue were identified and/or if
interstitial and/or endothelial expression of CAMs was
enhanced. Endothelial expression of HLA-1, HLA-DR
and ICAM-1 was semiquantitatively scaled 1 to 3, accord-
ing to intensity of immunoperoxidase staining of endothelial
cells. Endothelial CAM-expression grade 1 represents faint
staining (normal), grade 2 represents intense staining, and
grade 3 represents abundant immunoreactivity (Fig. 1). As
HLA-1, HLA-DR and ICAM-1 are constitutively ex-
pressed on endothelial cells, expression was enhanced, if
immunoreactivity staining exceeded grade 1. The criteria for
endothelial activation were met if, for two or more CAMs,
immunoreactivity staining exceeded grade 1. Endothelial
activation was graded according to the sum of endothelial
expression of HLA-1, HLA-DR and ICAM-1: 3 to 4
normal, 5 to 7 moderate, 8 to 9 abundant. The myocardial
biopsies were examined and analyzed by two independent
blinded observers.
Endothelial function. Endothelial function of the radial
artery was assessed. By means of high-resolution ultrasound,
diameter changes in response to reactive hyperemia (flow-
mediated vasodilation [FMD]), as compared with glycerol-
trinitrate (GTN) (endothelium-independent vasodilation
[GTN-MD]), were detected, referring to the standard
protocols (26,27). Accuracy and reproducibility have been
documented (27); a low coefficient of variation for measure-
ments of arterial diameter and a high correlation between
consecutive control measurements have been demonstrated
(26). Flow-mediated vasodilation in response to reactive
hyperemia (FMD) represents endothelium-dependent va-
soreactivity, whereas vasodilation in response to GTN
(GTN-MD) indicates smooth muscle cell function and is
Abbreviations and Acronyms
CAM  cell adhesion molecule
Co  control group
ECG  electrocardiogram
EF  ejection fraction
FMD  flow-mediated vasodilation
GTN  glyceroltrinitrate
GTN-MD  glyceroltrinitrate-mediated vasodilation
HLA  human leukocyte antigen
ICAM  intercellular adhesion molecule
MC  myocardial inflammation
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independent of endothelial function. Reactive hyperemia,
induced by distal cuff occlusion and release, leads to a release
of endothelium-dependent vasodilator substances mediated
by shear stress, rather than ischemic metabolites. This
endothelium-dependent vasodilation can be blocked by the
nitric oxide synthase-inhibitor N(G)-monomethyl-L-
arginine (23,22). As the vessel diameter after reactive
hyperemia is usually maximal after 45 s to 60 s, when flow
velocity has already normalized, vasodilation is not due to
physical requirements of enhanced flow (13,26,27).
TECHNICAL SETTINGS. The radial artery was examined by
two-dimensional ultrasound images, with a 10-MHz linear
array transducer and a standard 128XP/10c-system (Acu-
son, Mountain View, California). The transducer was po-
sitioned distal to the elbow to achieve a longitudinal picture
of the radial artery. Transmit zone, depth and gain were set
to optimize images of the lumen/arterial-wall interface;
images were magnified by resolution box function; machine
operating parameters were not changed during the study.
Diameters were measured by means of a computerized edge
detection program (Cardiovascular Imaging Software,
Information-Integrity, Boston, Massachusetts); the images
were acquired ECG-triggered at end-diastole throughout
the study. Arterial flow velocity was measured by pulsed
Doppler signal at a 70° angle to the vessel throughout the
study.
STUDY PROTOCOL. The subject lay at rest for at least 10
min before beginning the scan for endothelial function. A
resting scan was recorded for 1 min. A pneumatic tourni-
quet, placed at the subject’s wrist, was then inflated to a
pressure of 300 mm Hg for 3 min. The release immediately
induces increased blood flow in the subject’s forearm for few
seconds, which represents the stimulus for endothelium-
dependent vasodilation. Vasodilation is generally maximal
after 60 s, when flow has already normalized. The vessel was
continuously scanned during the procedure, from baseline
until 5 min after release of the cuff. A break of 10 min with
the patient continuously supine was required before the scan
for endothelium-independent vasodilation was started. Af-
ter a resting scan, 400 g GTN was administered sublin-
gually; the scan continued for 5 min after application.
Maximal vasodilation generally occurs 4 min to 5 min after
GTN administration. One experienced person performed
all scans. The computer-assisted calculation of vessel diam-
eters was conducted in a blinded fashion. The ECG was
monitored continuously, and blood pressure was controlled
throughout the study. All cardiovascular medication was
ceased 12 h to 48 h before the study, depending on half-life.
CALCULATIONS. Flow-mediated vasodilation represents the
percentage of diameter increase caused by shear stress,
compared with baseline. The GTN-MD represents the
percentage of diameter increase induced by GTN, com-
pared with baseline. Flow was calculated from Doppler flow
velocity and vessel diameter. Reactive hyperemia was calcu-
lated as the maximum flow recorded within the first 15 s
after cuff deflation divided by flow during the baseline scan.
Statistical analysis. Statistical analysis was performed with
the SPSS Inc. (Chicago, Illinois) software, version 10.0 for
IBM-PC. Descriptive data are expressed as mean  SD.
Quantitative data were correlated by use of the Spearman p
rank-order analysis, calculating the coefficient of correlation
r. Quantitative data were compared to qualitative data by
use of the Kruskal-Wallis test on rank sums for independent
samples, followed by a post-hoc multiple comparison pro-
cedure, if appropriate. To compare quantitative data of two
groups, the Mann-Whitney U test was applied. Statistical
significance was inferred at p  0.01.
RESULTS
Patients characteristics. Mean age of the 53 patients was
44  13 years; 21 were men, 32 women, mean left
ventricular EF was 62  12% (Table 1). All patients were
normotensive and had normal lipid levels. Five subjects were
treated for hypertension, three for hypercholesterolemia,
three were smokers. The patients were on standard cardio-
vascular medication. There were no significant differences in
risk factors or medication between patients at different levels
of endothelial activation (Table 1).
Mean age of the 12 control subjects was 45  13 years;
six were men, six women, mean EF was 63  14% (Table
1). All patients were normotensive and had normal lipid
levels. Two subjects were treated for hypertension, one for
hypercholesterolemia, one was a smoker.
Myocardial biopsies. Myocardial inflammation was con-
firmed by immunohistology in 53 subjects, applying the
Figure 1. Myocardial biopsies with normal (left panel) versus enhanced (right panel) expression of endothelial cell adhesion molecules, as determined by
immunohistology. Magnification  400.
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criteria described above. A total of 12 subjects had normal
myocardial biopsies.
Endothelial activation, as demonstrated by enhanced
expression of HLA-1, HLA-DR and ICAM-1 in myocar-
dial biopsies, was detected in 43 (81%) of the 53 patients;
the extent and the pattern of distribution varied: 5 patients
had normal expression levels of HLA-1, HLA-DR and
ICAM-1, 6 had enhanced expression of only HLA-1, 7 had
enhanced expression of HLA-1 and HLA-DR, 11 had en-
hanced expression of HLA-1 and ICAM-1, and 24 had
enhanced expression of HLA-1, HLA-DR and ICAM-1.
The number of patients for each level of endothelial
activation is depicted in Table 1.
Endothelial function. GENERAL CHARACTERISTICS.
Heart rate (74  8 beats/min) and blood pressure (systolic
121  9 mm Hg, diastolic 74  8 mm Hg) did not change
significantly during measurements. Hemodynamic parame-
ters were not significantly different between controls and
patients with MC, nor between different levels of endothe-
lial activation. Adequate reactive hyperemia as a stimulus for
endothelium-dependent vasodilation was achieved in all
subjects. Mean resting diameter of the radial artery was 2.47
 0.47 mm; after reactive hyperemia the mean diameter
increased to 2.60 0.48 mm and after GTN to 3.11 0.49
mm (Table 1).
FMD. Endothelial function, as determined by FMD of the
radial artery, in patients with MC, was significantly im-
paired (FMDMC 4.28%), as compared with controls (FM-
DCo 10.10%) (Fig. 2) (p  0.001). The severity of endo-
thelial dysfunction in patients with MC correlates
significantly with the extent of endothelial expression of
HLA-1 (r  0.459, p  0.001), HLA-DR (r  0.287,
p  0.037) and ICAM-1 (r  0.385, p  0.004) in
myocardial biopsies (Fig. 3). With increasing, enhanced
expression of endothelial CAMs (sum score), endothelial
function was progressively impaired, as measured by de-
creasing FMD (r  0.433, p  0.001) (Table 1, Figs. 3
and 4).
Table 1. Patient Characteristics
Control MC
Endothelial activation (MC)
Normal Moderate Abundant
n 12 53 10 26 17
Hypertension (n) 2 5 1 2 2
Hyperlipidemia (n) 1 3 1 1 1
Smokers (n) 1 3 1 1 1
EF (%) 63  14 62  12 67  5 62  11 58  15
Age (yrs) 45  13 44  13 46  11 42  15 46  12
Gender (male/female) 6/6 21/32 4/6 10/16 7/10
d base (mm) 2.40  0.53 2.48  0.46 2.59  0.47 2.47  0.40 2.46  0.54
d max (mm) 2.64  0.56 2.59  0.47 2.78  0.49 2.56  0.41 2.53  0.55
d GTN (mm) 3.08  0.57 3.12  0.48 3.26  0.73 3.11  0.43 3.02  0.34
FMD (%)* 10.11  2.22 4.28  2.72 7.78  2.15 3.74  2.25 3.05  1.92
GTN-MD (%) 28.12  8.37 27.67  8.58 29.91  7.75 27.36  9.75 26.82  7.27
Data is expressed as mean  SD or absolute numbers (n). For patients with myocardial inflammation (MC), data is depicted
for different levels of endothelial activation. No statistically significant difference between different levels of endothelial activation
(normal, moderate, abundant) or between MC and control, concerning risk factors, ejection fraction (EF) (p  0.340/0.441),
age (p  0.430/0.723) or glyceroltrinitrate endothelium-independent vasodilation (GTN-MD) (p  0.614/0.754). *Statistically
significant difference for endothelium-dependent flow-mediated vasodilation (FMD) between different levels of endothelial
activation (normal, moderate, abundant) (p  0.001) and between MC and control (p  0.001).
d base diameter of radial artery at baseline; d GTN diameter of radial artery after GTN; d max diameter of radial artery
after reactive hyperemia.
Figure 2. Endothelium-dependent, flow-mediated vasodilation (FMD) (left panel) and glyceroltrinitrate endothelium-independent vasodilation (GTN-
MD) (right panel) in peripheral arteries in patients with myocardial inflammation (MC) as compared with patients with normal myocardial biopsies
(Control). Significant difference for FMD (p  0.001); no significant difference for GTN-MD.
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GTN-MD. Endothelium-independent vasodilation in pa-
tients with MC (GTN-MDMC 27.67 8.58) did not differ
significantly from endothelium-independent vasodilation in
controls (GTN-MDCo 28.12  8.37) (Fig. 2) (p  0.754).
There was no significant correlation between endothelium-
independent GTN-MD of peripheral arteries and the
extent of endothelial expression of HLA-1 (r  0.178,
p  0.202), HLA-DR (r  0.014, p  0.922), ICAM-1
(r  0.085, p  0.546) or the sum score of CAM
expression (r  0.099, p  0.480) in myocardial biopsies.
IMPACT OF LEFT VENTRICULAR FUNCTION. In patients
with MC, left ventricular function, as determined by EF in
left ventricular angiography, had an effect on endothelium-
dependent vasodilation, as well as endothelium-
independent vasodilation; there was a significant correlation
between FMD and EF (r  0.414, p  0.002), as well as
GTN-MD and EF (r  0.299, p  0.030). However, there
were no significant differences in left ventricular function
(EF), comparing the different patient groups according to
the levels of endothelial activation (Table 1). Additionally,
there was no significant correlation between EF and endo-
thelial activation, as determined by endothelial expression of
HLA-1 (r  0.062, p  0.660), HLA-DR (r  0.019,
p 0.895), ICAM-1 (r0.261, p 0.059) and the sum
score of endothelial activation (r  0.174, p  0.212).
IMPACT OF AGE. As all subjects in our study population
were middle-aged, with only small variations, age had no
impact on endothelial function. In patients with MC, there
was no significant correlation between age and endothelial
function (r  0.033, p  0.816) nor between age and
endothelial activation (r  0.097, p  0.489). There were
no significant differences in age comparing the different
patient groups according to the levels of endothelial activa-
tion (Table 1).
DISCUSSION
The results of this study demonstrate a systemic endothelial
dysfunction in patients with immunohistologically con-
firmed MC. For the first time, endothelial activation in
myocardial biopsies has been associated with systemic en-
dothelial dysfunction in patients with MC. The severity of
endothelial dysfunction correlates with the extent of endo-
thelial expression of HLA-1, HLA-DR and ICAM-1.
As other factors with impact on endothelial function have
been minimized or excluded in this study, we interpret our
findings towards a direct interaction between endothelial
activation by inflammatory processes and endothelial dys-
function. Endothelium-independent vasoreactivity was not
affected by MC or endothelial activation.
The impact of systemic inflammation (6,7,9) or circulat-
ing systemic inflammatory markers like C-reactive protein
(8) and tumor necrosis factor-alpha (28,29) on endothelial
function has been demonstrated for other diseases.
Cytokine-stimulated adhesion molecule expression has been
observed in cultured human cardiac endothelial cells (30).
Similar mechanisms may play a role for endothelial dysfunc-
tion in patients with MC. Endothelial dysfunction of
peripheral arteries in patients with MC could either be
caused by systemic endothelial CAM expression due to
generalized vascular inflammation or by circulating cyto-
kines induced by the inflammatory process in the heart.
Figure 3. Endothelium-dependent, flow-mediated vasodilation (FMD) in peripheral arteries in relation to endothelial expression of human leukocyte
antigen (HLA)-1, HLA-DR and intercellular adhesion molecule (ICAM) in myocardial biopsies of patients with myocardial inflammation. Significant
differences (p  0.05).
Figure 4. Endothelium-dependent, flow-mediated vasodilation (FMD) in
peripheral arteries in relation to endothelial activation (sum score) in
myocardial biopsies (Co). Significant correlation (r 0.656, p  0.001).
MC  myocardial inflammation.
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A correlation between coronary and peripheral endothe-
lial function has been demonstrated for arteriosclerosis (12).
Our recent research is focused on investigating these rela-
tions in patients with MC.
Consistent with the literature (17–21,22), we found a
correlation between endothelial dysfunction and left ven-
tricular dysfunction. As left ventricular function was equally
mildly impaired in all groups with different levels of endo-
thelial activation, this did not alter our results with respect
to the effect of endothelial activation and inflammation on
endothelial function. Endothelial activation and left ventric-
ular function, both, independently from each other, predict
endothelial dysfunction in patients with MC.
To interpret our findings within a clinical context, it is
important to understand that endothelial dysfunction po-
tentially represents a marker of prognostic relevance (1,3,4).
For patients with ischemic heart disease and after transplan-
tation, this has already been demonstrated (1–5); for pa-
tients with MC, it remains to be verified.
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